TB VACCINES WORKING GROUP

Slides:



Advertisements
Similar presentations
aerobic.,AFB, NO Gram stain, 60% Lipid GT=8-24 hrs
Advertisements

Research and Innovation Research and Innovation Tuberculosis Vaccine Development in Denmark Joshua Woodworth Post Doctoral Fellow Marie Curie IIF Statens.
BCG and Other Candidate Vaccines for Tuberculosis RajKumar Kayal Guwahati.
Tuberculosis in Children: Prevention Module 10C - March 2010.
Latent TB When infected with M Tuberculosis, but do not have active tuberculosis disease. Patients are not infectious. TB infections in Australia are predominantly.
Adriana Weinberg, MD University of Colorado Denver.
Potential prophylactic BCG Prime-booster Gaëlle Noël Kidist Bobosha Subgroup A2 March 16 th, 2011.
TB Presentation for Healthcare Students
New TB Vaccines: Necessity, Possibility and Risk Tanapat Palaga, PhD Department of Microbiology Faculty of Science Chulalongkorn University NVI: 11/07/12.
Prevention Bacille Calmette Guerin (BCG) Vaccine Live attenuated strain of Mycobacterium bovis; 1921 Efficacy Clinical trials UK: protective effect of.
MD: Universidad Autónoma de Guadalajara, México, 1975 MPH: Graduate School of Public Health, San Diego State University, 1990 Pulmonologist, Hospital General.
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town.
TUBERCOLOSIS Agis Terzidis, Paediatrician Spyridon Gialamas, Medical Doctor SEMINAR ON TROPICAL AND TRAVEL MEDICINE AT TTCIH IFAKARA 25 JUNE 2009.
TUBERCULOSIS Paige Derouin. History Began infecting the first human ancestors as long as 500,000 years ago In 1882 – claimed the lives of 1 in 7 people.
The status of progress towards new TB vaccines Hassan Mahomed South African Tuberculosis Vaccine Initiative, University of Cape Town but also on behalf.
BCG complications.
This is a global infectious disease.
+ Tuberculosis: Quick Facts. + Tuberculosis: Reflection How does TB affect a person’s health? How does TB affect a person’s life, socially? What problem.
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
Pulmonary tuberculosis
Development of an oral vaccine against tuberculosis for use in badgers (Meles meles) Dr Eamonn Gormley, UCD Dublin.
Problems and prospects of development of the subunit TB vaccine
Pediatric Immunization (EPI) Garcia, Garzon, Gaspar, Gatchalian, Gaw, Geraldoy, Geronimo, Geronimo, Geronimo.
Julio A. Ramirez, MD, FACP Professor of Medicine Chief, Infectious Diseases University of Louisville Chief, Infectious Diseases Veterans Affairs Medical.
TASK FORCE ON RETOOLING STOP TB PARTNERSHIP Cape Town November 2007.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Prophylatic vaccine replacing conventional BCG Delphine Noël Vanessa Infante Surendra Karki.
American Journal of Respiratory and Critical Care Medicine 2000 Vol. 161, pp
Tuberculosis By: Megan and KC. Tuberculosis There are 2 phases: latent TB and active TB. Latent TB is when it first enters the body and isn’t harmful,
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student under Nephrology Division under the supervision and administration.
Horng-Yunn Dou( 杜鴻運 ) Division of Infectious Disease National Health Research Institute Immune Regulation and Vaccine Development : Tuberculosis as an.
Preclinical evaluation of safety, efficacy, immunogenicity of a recombinant rBCG Pasteur B vaccine Group B4 March 16, 2011 Adane Miheret, Tewodros Tariku.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Module 2 TB Disease Transmission & Prevention. Pulmonary Tuberculosis Extra -Pulmonary TB an infectious disease caused by a microorganism called Mycobacterium.
Harvard University Initiative for Global Health Global Health Challenges Social Analysis 76: Lecture 8.
Tuberculosis August 17, 2010 Tuberculosis Mycobacterium tuberculosis – Fastidious, aerobic, acid-fast bacillus Tremendous increase in incidence over.
Latent Tuberculosis and Tuberculosis Postgraduate course: Diagnosis and treatment of tuberculosis, April 23, 2008 Hans L Rieder Department of Tuberculosis.
Meeting of the Working Group on TB Drug Development Why you need to be engaged? Marcos Espinal Executive Secretary Stop TB Partnership 29 October 2004.
Tuberculosis In Thailand By Junior Sethasathien. What is tuberculosis(TB)? An infectious disease that mainly affects the lungs Cause by a bacteria Spread.
WG report backs: New TB Vaccines & TB/HIV INAT Meeting November 12, 2010 Berlin.
Mycobacterium.
Tuberculosis in Children and Young Adults
The death of a disease TB(tuberculosis).
BCG Vaccination Dr Lika Nehaul. Acknowledgements Nature (Scientific) Publishing Group Health Protection Agency World Health Organisation.
$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.
TB: The Elispot In The Room Dr Jessica Potter TB Research Registrar Barts Health NHS Trust.
Chapter 20 Mycobacterium
Tuberculosis in children
Tuberculosis (TB) PHCL 442 Lab Discussion 4 Raniah Al-Jaizani M.Sc.
Tuberculosis prevention
BCG VACCINATION.
Pulmonary Tuberculosis (TB)
New Approaches to TB Vaccination
Tuberculosis prevention
Mycobacterium. Mycobacterium Important Human Pathogens Mycobacterium tuberculosis Mycobacterium leprae (uncommon) Mycobacterium avium-intracellulaire.
Epidemiology of pulmonary tuberculosis
بسم الله الرحمن الرحيم.
? Neutralizing Antibodies: Research pathways in 2013 and beyond
The RD1-encoded antigen Rv3872 of Mycobacterium tuberculosis as a potential candidate for serodiagnosis of tuberculosis  P. Mukherjee, M. Dutta, P. Datta,
Housekeeping May 1st 31 field trip, transport yourself to the Shady Lakes, pm. PCR results gel is posted (report) This lecture paper discussion.
PPE protein (Rv3425) from DNA segment RD11 of Mycobacterium tuberculosis: a potential B-cell antigen used for serological diagnosis to distinguish vaccinated.
Critical research concepts in tuberculosis vaccine development
DIFFERENT STAGES OF BCG VACCINE BY MBBSPPT.COM
IMMUNE RESPONSE TO MYCOBACTERIAL INFECTION
Division of AIDS Office of the Director Workforce Operations,
BCG Vaccination Dr Lika Nehaul CCDC / NPHS TB Programme Lead
Tuberculosis.
OPTIMIZING THE QUALITY OF CARE FOR CHILDREN WITH TUBERCULOSIS Dr
Presentation transcript:

TB VACCINES WORKING GROUP Douglas Young Stop TB Partners’ Forum New Delhi March 2004

live attenuated Mycobacterium bovis bacillus of Calmette and Guerin BCG VACCINE live attenuated Mycobacterium bovis bacillus of Calmette and Guerin

BCG provides some useful level of protection against childhood TB BCG provides little or no protection against adult pulmonary TB

X Primary tuberculosis, post-primary tuberculosis, and BCG disease immune response disease reactivation reinfection 1° disease X disease BCG infection bacterial load few weeks months/years/decades

1. prevent establishment Profile of improved tuberculosis vaccines disease disease disease bacterial load 1. prevent establishment of initial infection 2. prevent progression from latent infection to active disease

attenuated mycobacteria preclinical screening of 268 TB vaccine candidates attenuated mycobacteria (25) recombinant vaccines (29) DNA vaccines (43) purified proteins (114) Ian Orme, Colorado State University

two new TB vaccine candidates are now in phase I clinical trials

Vaccine Expectations

partially protective vaccine + improved diagnostics + new drugs clinical trials: opportunity for capacity strengthening

Vaccine Working Group Activities provide an international forum for discussion of vaccine issues economic case for TB vaccines standardised regulatory requirements trial site directory immunological assays BCG interactive website